- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Defining Future Needs for Real-World Evidence in mCRC
Panelists discuss how future RWE should expand to include survival, quality of life, and safety data to improve third-line mCRC care.
EP: 1.Overview of Available Third-Line Options in mCRC
EP: 2.Evidence Supporting FTD/TPI ± Bevacizumab in mCRC
EP: 3.Efficacy of Fruquintinib and Comparisons Across Agents in mCRC
EP: 4.Selecting Among Third-Line Therapies in Clinical Practice for mCRC
EP: 5.Leveraging Real-World Evidence in Sequencing Decisions for mCRC
EP: 6.Translating Real-World Outcomes in mCRC Into Patient Conversations
EP: 7.Incorporating Patient-Reported Outcomes in mCRC Into Shared Decision-Making
EP: 8.Real-World Evidence in mCRC: Special Populations and Safety Assessment
EP: 9.Defining Future Needs for Real-World Evidence in mCRC
EP: 10.Applying Third-Line Therapy in mCRC: Community vs Academic Settings
Panelists identify gaps in current evidence and the need for more comprehensive real-world data to guide third-line therapy in metastatic colorectal cancer (mCRC).
They suggest future real-world evidence (RWE) should capture not only survival outcomes but also patient-reported quality of life, adherence, and broader safety signals.
Such data could enhance treatment personalization and support health system adoption of evidence-based third-line strategies.
Cefdinir Nearly Doubles Outpatient Uncomplicated UTI Treatment Failure Compared With Cephalexin
November 11th 2025Cefdinir is linked to nearly double the outpatient uncomplicated UTI treatment failure of cephalexin, with higher recurrence and increased resistance to other cephalosporins.
Read More
